Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Free In-Person Regional Events Focused on Oncology and Population Health

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

ADA Insights: Strategic T1D Screening and Management : Episode 7

Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

April 16, 2024

Opinion

Video

Robert Gabbay, MD, PhD, gives closing thoughts and advocates that continuous glucose monitors should be supplied for all insulin-dependent diabetes patients, including at initial diagnosis, to facilitate self-management and tighter control of this disease.

EP: 1.Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

EP: 2.Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

EP: 3.Identifying Risk to Enable Early Detection of Type 1 Diabetes

EP: 4.Challenges in Autoantibody Screening for Type 1 Diabetes

EP: 5.Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

EP: 6.Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Now Viewing

EP: 7.Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Related Content

β-blockers were not associated with improved outcomes in patients with acute MI and preserved LVEF, according to a new meta-analysis published in JAMA Cardiology. | Image Credit: @Elena_stock.adobe.com.jpg

β-Blockers Show No Added Benefit After MI With Preserved LVEF

January 7th 2026

Article

A meta-analysis found β-blockers did not improve clinical outcomes in patients with acute MI and preserved LVEF, raising questions about routine use.

Switching From MA to TM Increases Mental Health Care Use: Angela Liu, PhD, MPH

December 23rd 2025

Podcast

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Listen

Nimbus Therapeutics and Eli Lilly announced their partnership to develop a novel oral drug for patients with obesity and other metabolic diseases. | Image credit: ARMMY PICCA_AdobeStock.jpeg

Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug

January 6th 2026

Article

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025

Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

Related Content

β-Blockers Show No Added Benefit After MI With Preserved LVEF

January 7th 2026

Article

A meta-analysis found β-blockers did not improve clinical outcomes in patients with acute MI and preserved LVEF, raising questions about routine use.

Switching From MA to TM Increases Mental Health Care Use: Angela Liu, PhD, MPH

December 23rd 2025

Podcast

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Listen

Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug

January 6th 2026

Article

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025

Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen